Italian biotech company Amplimedical signs on as Roche's new PCR licensee:
This article was originally published in Clinica
Amplimedical, the Italian biotechnology company, has gained non-exclusive worldwide licence to Roche Diagnostic's real-time PCR technology. Milan-based Amplimedical plans to use this deal to expand further its product portfolio - of which nearly half comprise real-time assays - and become a major supplier of highly automated and rapid diagnostic technology.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.